Kyorin commences a new joint research project with Scottish Biomedical
July 31, 2002
Kyorin Pharmaceutical Co., Ltd. (President: Ikuo Ogihara) is pleased to announce that Kyorin has entered into, as of the 16th day of July 2002, development agreement with the Scottish Biomedical Foundation Limited (Scottish Biomedical) to identify and optimize novel drug candidates in the area of metabolic diseases (for type-2 diabetes) at Kyorin Scotland Research Laboratory.
Kyorin currently focuses its scope of R&D segments on three fields, such as infectious diseases, immunology & allergy and metabolic diseases under its franchise management strategy. Kyorin is developing a new drug discovery networks with leading discovery research institutes in US, EU and Japan and is taking a policy to explore drug seeds more efficiently. Kyorin Scotland Research Laboratory was established in conjunction with Scottish Biomedical in November 2000 in which we can conduct the discovery research, being linked with the technology from the six principle Universities in Scotland.
Adobe Reader software is required to view and print PDF files. The latest version of Adobe Reader can be downloaded by accessing the Adobe Systems Incorporated website.